Background: Many studies had discovered that early onset severe preeclampsia (EO-PE) has worst maternal and neonatal outcome compared to late-onset type (LO-PE), related to its placental involvement. Severe preeclampsia was defined as newly onset severe hypertension developed after 20 weeks gestation in previously normal blood pressure women, with coexistence of proteinuria, or maternal organ or uteroplacental dysfunction. Hemeoxygenase-1 (HO-1) is an enzyme with multiple effect which is protective to pregnancy.
Introduction
Preeclampsia is a major contributor of maternal and fetal morbidity and mortality worldwide. 1 Recently preeclampsia is classified based on the onset of the disease into early onset preeclampsia (EO-PE) <34 week gestation and late onset preeclampsia (LO-PE) >34 week. These two type of preeclampsia were suspected to have a different pathophysiology, clinical manifestation and outcome. 2, 3 EO-PE occurs mainly due to abnormal placentation which can be caused by reduced of cell protective factors (such as nitrite, hemeoxygenase-1 (HO-1)), or oxidative stress, genetic, environmental and immunological factors. 2, 4 Whereas LO-PE is associated with underlying maternal disease coexisted in pregnancy, rather than abnormal placental development. 2, 3 Earlier study mentioned that there were two protective pathways in pregnancy, namely the hemeoxygenase-carbon monoxide/HO-CO pathway and the cysthathione-γ-lyase pathway. 4 Deficiency in this protective pathway will lead to abnormal development of placental vascular system, eventually ended in preeclampsia. HO-1 is an enzyme that degrades free heme to produce a number of carbon monoxide (CO), iron (Fe 2+ ), and biliverdin through cytochrome P450 reductase (CPR). 4, 5 The in vivo and in vitro studies showed that HO-1 functions as a cytoprotector by degrading free heme which is highly reactive cytotoxic substance, and produces CO as a mediator of inhibiting inflammatory and apoptotic processes. 4 HO-1 is expressed in the syncytiotrophoblast and involved in placental cell protection and relaxation of blood vessels during pregnancy. 6 In preeclampsia, there is a disruption of regulation and development of placental blood vessels which is thought to be caused by reduced expression of HO-1 in the placenta. In this study we measure plasma HO-1 levels of umbilical cord and fetal outcome in EO-PE, LO-PE and normal pregnancy, to determine the role of placental HO-1 in the pathogenesis of preeclampsia and its relation to the clinical outcome.
Materials and methods
This is a comparative analytic observational study with cross sectional method, comparing HO-1 levels of umbilical cord blood of newborns and neonatal outcome in EO-PE, LO-PE and control groups (early onset-normal preganncy (EO-NP) and late onset-normal pregnancy (LO-NP) 7 While the exclusion criteria were pregnant women who had an co-existing diseases (such as metabolic diseases, systemic diseases, autoimmune, gynecological infections and tumors), refuse to be involved in the research, smokers and multiple pregnancies. The sample size of each group was 10 patients, based on previous related study. 8 The sampling in severe preeclampsia groups was done by consecutive sampling method, while in control group was carried out using a simple randomized method. As much as 5 cc of plasma umbilical cord was taken as soon as the baby is born and then HO-1 levels were examined by enzymelinked immunosorbent assay (ELISA) (StressXpress ELISA kit, StressMarq Biosciences Inc, Victoria, Canada). Babies were followed until they were discharged from the hospital, and neonatal composite morbidity was assessed. Neonatal composite morbidity consisted of: Apgar score <3, baby birthweight <2000 gram, neonatal length of stay >5 days, respiratory distress syndrome, jaundice and neonatal death. Apgar score was measured of the fetal clinical performance on 1 st minute, based on appearance, pulse, grimace, activity, and respiratory. 9 Respiratory distress syndrome was diagnosed based on clinical sign of dyspnea, grunting, tachypnea (respiratory rate >60x/minutes), chest indrawing, cyanosis, laboratory, and chest-x ray. Data was analyzed using Anova test, post hoc Tamhane test, Kruskal Wallis test, Fisher exact test, and eta association test to evaluate the different and the associatioan between each variable (SPSS 23, SPSS Inc., Illinois, USA).
Results

Characteristics of Research Samples
Based on the data in Table 1 , we found a significant differences in the age of the patients between EO-PE vs. EO-NP (p<0.001), the number of gravidity between the EO-PE vs. EO-NP (p=0.012) and EO-PE vs. LO-PE (p=0.041). BMI between LO-PE vs. LO-NP was also significantly different (p=0.010), while other parameters did not show any significant different.
EO-NP (n=10) EO-PE (n=10) LO-NP (n=10) LO-PE (n=10)
Plasma Umbilical Cord Hemeoxygenase-1 (HO-1)
Plasma umbilical cord HO-1 level of EO-PE (0.96±0.37 ng/ mL) was significantly lower compared to EO-NP (2.43±0.58 ng/mL; p<0.001), and LO-PE (2.18±1.07 ng/mL; p=0.034). While plasma umbilical cord HO-1 in LO-PE was not different with LO-NP, although tend to be lower ( Figure 1 , Table 2 ). The lowest HO-1 level was found in EO-PE group (0.55 ng/mL), and the highest was in LO-NP (3.86 ng/mL).
Neonatal Outcome
In term of neonatal outcome, there were significant differences in Apgar scores (p=0.008), baby birth weight (p<0.001), and length of stay (p=0.001), between EO-PE and LO-PE (Table 3) . And the length of stay of LO-PE was longer than LO-NP (3 vs. 2.5; p=0.038). But there were no significant differences in apgar score and baby birth weight between EO-PE vs. EO-NP, and LO-PE vs. LO-NP.
The assessment of neonatal composite morbidity includes low Apgar score (Apgar score <3), low birth weight (birth weight <2000 grams), length of stay >5 days, complications in newborns at hospital, such as respiratory distress syndrome, neonatal jaundice, and neonatal death. Any occurrence of these variable on baby indicating 
Discussion
This study support the hypothesis that EO-PE has a different pathogenesis compared to LO-PE, which is involvement of placenta. Plasma umbilical cord HO-1 can represent the level of placental HO-1, and the lower placental HO-1 is correlated with abnormal placental blood vessel development and inadequate vascularization. Our study reveal that in EO-PE group the plasma umbilical cord HO-1 level was lower than LO-PE and EO-NP. While HO-1 level in LO-PE was not different with LO-NP. Many studies (animal model and human) had already proven that deficiency of placental HO-1 were correlated with smaller spiral arteries, inadequate placental vascularization, different placental angiogenic profile, and significantly higher blood pressure, which is the main feature of placental preeclampsia. [10] [11] [12] Placental tissue of preeclampsia pregnant women has already proven to have a lower expression of HO-1, lower mRNA HO-1, and lower HO-1 protein level compared to normal pregnancy. 6, 13, 14 Deficiency HO-1 may also shift the balance toward anti angiogenesis dominant, which result in endothelial cell damage through its relation with soluble FMS like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng). 15 Cudmore, et al., showed that induction of HO-1 in human umbilical endothelial vein endothelial cells (HUVECs) inhibit the release of sFlt-1 and sEng. 16, 17 Circulating sFlt-1 and sEng are the two main factors in the development of clinical syndrome of preeclampsia. Our study result indicating that in EO-PE (but not in LO-PE) the placenta was involved, reflected by the lower level of plasma HO-1. This placental vascular involvement in EO-PE will decrease uteroplacental blood flow, lead to uteroplacental insufficiency and correlate with poor pregnancy outcome.
18 While LO-PE is associated with normal placental vascular development, normal uteroplacental perfusion, normal placental volume and better pregnancy outcome. 2, 19 Our study support this hypothesis with the finding that neonatal outcome and composite morbidity in EO-PE was worse compare to the LO-PE and EO-NP. Baby delivered from EO-PE woman had lower Apgar score, lower birth weight, and longer length of stay compared to LO-PE. Since neonatal morbidity also closely related to gestational age at the time of delivery, more severe form of EO-PE often necessitate iatrogenic preterm delivery, which result in prematurity. Prematurity will directly increase neonatal morbidity (respiratory distress syndrome, neonatal jaundice) and mortality. Our finding is in line with many recent studies which stated that neonatal outcome in EO-PE was worse compared to LO-PE. [19] [20] [21] And also the neonatal outcome in LO-PE was not different with the LO-NP, indicating relatively normal placental development and uteroplacental perfusion in this type of preeclampsia.
This study also reveal a strong correlation between plasma umbilical cord HO-1 level with neonatal composite morbidity. It means that low umbilical cord HO-1 level is correlated with poor neonatal outcome. Many studies had proven that deficiency HO-1 in placenta and circulation was correlated with poor pregnancy outcome, such as miscarriage, intra uterine growth restriction, intra uterine fetal death, and preterm labour. [22] [23] [24] [25] [26] [27] This might be explained by an unopposed free fetal heme on deficient HO-1 placenta that stimulates cell damage, subsequently lead to abnormal placentation. 27 But as far as we know, this was the first study to evaluate the relationship between placental HO-1 and neonatal outcome. The strong relationship between low level of placental plasma HO-1 and neonatal composite morbidity (especially in EO-PE) could provide clue about the role of placental HO-1 deficiency in the development of more severe type of preeclampsia with abnormal placental development and poor neonatal outcome. Defficiency of placental HO-1 was correlated with increased level of sFlt-1 and sEng, which associated with clinical severity of preeclampsia. 4 Study on animal model showed that induction of HO-1 inhibit sFlt-1 and sEng level, increased VEGF level, improved endothelial fuction, and decreased blood pressure. 16, 17, 28 Our study result indicate that in the future, HO-1 inducer (statin) may be used to protect the normal placental vascular development in pregnancy, prevent placental insufficiency syndrome such as preeclampsia (especially the early type), and improve the neonatal outcome.
Conclusion
This study reveal that defficiency placental HO-1 is correlated with poor neonatal outcome (especially in EO-PE) via abnormal placental vascular development. HO-1 inducer (statin) should be consider as a new approach in the future to protect vascular placental insufficiency, prevent subsequent preeclampsia syndrome, and improve neonatal outcome.
